About surgery for upper urinary tract urothelial cancer (UTUC)

Surgery is usually the main treatment for upper urinary tract urothelial cancer (UTUC) that has not spread to distant parts of the body.

Surgery may be open or keyhole (laparoscopic).

Open surgery

During open surgery, the surgeon makes 1 or 2 large cuts (incisions).

Keyhole (laparoscopic) surgery

During keyhole surgery, the surgeon makes 3 to 5 small cuts. They pass a laparoscope through one of the cuts. A laparoscope is a thin tube with a light and camera on the end. It sends video images to a monitor. Then the surgeon passes special surgical tools through the other cuts to remove the cancer.

 

Having a laparoscopy
Image: Having a laparoscopy

The surgeon may use a specialised machine to help with keyhole surgery. There are instruments attached to the machine, which the surgeon controls. This is called robot-assisted surgery. It makes it possible for the surgeon to do very precise surgery.

Recovery from keyhole surgery is usually quicker than recovery from open surgery. This is because the wounds are smaller.

Some types of keyhole surgery may only be available at larger cancer centres. This means you may have to travel for your treatment. Your surgeon will talk to you about which type of surgery is best for you.

See also

Removing the whole kidney and ureter (nephroureterectomy)

This is the most commonly used operation to treat UTUC. The surgeon removes:

  • the kidney
  • a layer of fat around the kidney
  • the ureter
  • an area of tissue where the ureter enters the bladder (bladder cuff).

In keyhole surgery to remove the whole kidney and ureter, the surgeon makes 3 to 5 small cuts. They pass a laparoscope through one of the cuts. One of the cuts may be bigger so that the surgeon can remove the kidney and ureter. 

The surgeon may also remove some lymph nodes close to the kidney to check whether they contain cancer cells. 

You will have a tube (catheter) put in during the operation to drain urine from your bladder. This may be removed before you leave hospital. But you may go home with it still in place to let your bladder heal.

You may have one dose of chemotherapy into the bladder after your surgery. This is to help prevent the cancer coming back. This is called intravesical chemotherapy. If you have a low risk of the cancer coming back, you usually do not need chemotherapy.

If you have keyhole surgery, you may stay in hospital for 2 to 5 days. If you have open surgery, you may stay in hospital for 5 to 7 days.

Removing a kidney and ureter is a big operation. It is not suitable for everyone. Your doctors may need to do tests to check you are well enough to cope with the surgery. 

You can live a normal life with just one kidney. It will be able to do the work of both kidneys.

Removing part of the ureter (segmental resection)

You usually have this type of surgery only if the cancer is in the lower third of the ureter.

The surgeon removes the part of the ureter where the tumour is. They also remove a healthy area (margin) of ureter above the tumour and all the ureter below the tumour. Then they reattach the remaining ureter to the bladder.

This is less common than having the whole kidney and ureter removed.

Endoscopic surgery

It is sometimes possible to remove a low-grade, early-stage tumour in the renal pelvis using endoscopy. The surgeon passes a flexible tube called an endoscope up through the urethra, bladder and ureter to the renal pelvis. This is called a ureteroscopy. The surgeon then removes the tumour using tools passed through the endoscope.

Sometimes the surgeon makes a small cut in your back to reach the kidney (percutaneous renoscopy). They then pass the endoscope into the kidney to reach the renal pelvis.

You may have endoscopic surgery for higher-grade cancers if you only have one kidney. Or you may have it if your kidneys do not work well enough for you to cope with just one.

Endoscopic tumour ablation

If the cancer is low grade and only growing on the lining of the ureter, you may have it removed by laser or heat treatment (diathermy). This is called ablation. 

A doctor passes a ureteroscope into the bladder and into the ureter. They then apply a beam of laser or heat to the tumour to destroy it.

Sometimes a tube (stent) may be left in the ureter for a time to keep it open.

If you have laser or heat treatment, you will be very closely monitored afterwards. This is because there is a risk the cancer could grow back. If this happens, it is important the cancer is found as soon as possible.

See also:

About our information

  • References
    Below is a sample of the sources used in our upper urinary tract urothelial cancer (UTUC) information. If you would like more information about the sources we use, please contact us at cancerinformationteam@macmillan.org.uk
    European Association of Urology. Upper urinary tract urothelial carcinoma guidelines. EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. Available from www.uroweb.org/wp-content/uploads/Upper-Urinary-Tract-Urothelial-Carcinoma-large-text-V3.pdf (accessed April 2021).
    National Institute for Health and Care Excellence (NICE). Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable. Technology appraisal guidance (TA492). Published 06 December 2017. Last updated 12 July 2018. Available from www.nice.org.uk/guidance/TA492  (accessed April 2021)
    Birtle A, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. The Lancet, 2020; 395, 10232, 1268-1277. Available from www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30415-3/fulltext (accessed June 2021).

 

  • Reviewers

    This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Dr Lisa Pickering, Consultant Medical Oncologist.

    Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.

Date reviewed

Reviewed: 01 November 2021
|
Next review: 01 November 2024
Trusted Information Creator - Patient Information Forum
Trusted Information Creator - Patient Information Forum

Our cancer information meets the PIF TICK quality mark.

This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.